Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

In Wilson disease (WD), copper accumulates in the liver and brain causing disease.

To better understand the mode of action of TTM, the researchers investigated its effects on copper absorption and biliary excretion.

Who Took Part

The study group was 16 volunteers.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the volunteers nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some volunteers received a placebo instead of Copper (Supplement), giving a reference point.

Changes in hepatic 64Cu activity reflected changes in intestinal 64Cu uptake.

What Was Measured

The subject headings attached to it are Hepatolenticular Degeneration, Copper, Positron Emission Tomography Computed Tomography, Healthy Volunteers, Chelating Agents, Choline and Molybdenum.

Author keywords: 64 copper, ALXN1840, Copper absorption, PET, WTX-101 and copper chelation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 16 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of hepatology), a journal based in Netherlands.

More context: the Copper (Supplement) compound page, all human trials.